Lenalidomide (Revlimid®)

DRUG6 trials

Conditions

Acute Myeloid LeukemiaHodgkin DiseaseMultiple MyelomaMultiple Myeloma, Newly DiagnosedMyelodysplastic Syndrome

Phase 1

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

H. Lee Moffitt Cancer Center and Research InstituteAcute Myeloid Leukemia, Myelodysplastic Syndrome

Start: 2009-06-25End: 2020-11-16Updated: 2020-12-22

Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

CompletedNCT01062152

TelikMyelodysplastic Syndrome

Start: 2009-11-30End: 2013-03-31Updated: 2013-06-06

Phase 2

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

CompletedNCT00478959

University Health Network, TorontoHodgkin Disease

Start: 2006-12-31End: 2014-06-30Updated: 2020-09-18

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

CompletedNCT00540644

Attaya SuvannasankhaMultiple Myeloma

Start: 2007-10-31End: 2014-08-31Updated: 2016-06-21

Phase 3

Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

CompletedNCT01916252

PETHEMA FoundationMultiple Myeloma

Start: 2013-09-30End: 2016-11-16Target: 460Updated: 2017-09-27

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

RecruitingNCT06918002

Intergroupe Francophone du MyelomeMultiple Myeloma, Newly Diagnosed

Start: 2025-07-09End: 2036-05-01Target: 824Updated: 2026-04-02

Blood2025-11-03

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Blood2025-11-03

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.

2025-10-012 citations

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Blood2024-09-1816 citations

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

2024-06-013 citations

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Blood2023-12-0427 citations

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

Frontiers in Oncology2023-11-0216 citations

Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling

Haematologica2023-08-304 citations

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

Blood Advances2022-02-1446 citations

FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

Blood Advances2021-09-2944 citations

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

Blood2020-07-21126 citations

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

Blood2020-04-1634 citations

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.

2019-10-01157 citations

PS1352 DISSECTING THE BONE MARROW IMMUNE MICROENVIRONMENT IN THE COMPLETE SPECTRUM OF MONOCLONAL GAMMOPATHIES: POTENTIAL IMPLICATIONS IN DISEASE PATHOGENESIS

HemaSphere2019-06-01

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease

Blood2019-04-2215 citations

Lenalidomide (Revlimid®)

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers